文献速递姑息放疗与转移瘤放疗物理与技术

消融性立体定向体部放疗1期剂量递增试验的长期结果

Long-Term Results of a Phase 1 Dose Escalation Trial of Ablative Stereotactic Body Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-12-25

这项前瞻性剂量递增试验纳入90例患者,其中52例(58%)为原发前列腺肿瘤、13例(14%)为乳腺肿瘤、25例(28%)为其他原发肿瘤类型,对所有可见淋巴结或非脊柱骨寡转移灶按3个连续队列分别给予5×7.0 Gy、3×10.0 Gy或1×20.0 Gy。中位随访50个月未见新的安全性信号,2级毒性分别为13%、7%和10%(P=0.9),无3至5级毒性;局部失败率分别为9%、3%和6%(P=0.5),4年局部失败累积风险7%(95%CI 2-12)。

要点

  • 中位随访50个月未见新的安全性信号,2级毒性分别为13%、7%和10%(P=0.9),无3至5级毒性。
  • 局部失败率分别为9%、3%和6%(P=0.5),4年局部失败累积风险为7%(95%CI 2-12)。
  • 中位无进展生存期16.5个月(95%CI 9.8-21.5),4年无进展生存率21%(95%CI 14-32)。

核心结论

  • 该试验支持对骨和淋巴结转移灶安全有效地使用剂量递增的单次立体定向体部放疗,尤其考虑到患者便利性和成本效益。
  • 鉴于乳腺和前列腺癌在本研究中代表性不足,将这些结果推广至乳腺和前列腺癌以外时需谨慎。

研究设计与样本

  • 前瞻性剂量递增试验,纳入90例患者,其中52例(58%)为原发前列腺肿瘤、13例(14%)为乳腺肿瘤、25例(28%)为其他原发肿瘤类型。
  • 所有可见淋巴结或非脊柱骨寡转移灶按3个连续队列治疗:5×7.0 Gy、3×10.0 Gy或1×20.0 Gy。

主要发现

  • 中位随访17.2个月的初步结果未发现剂量限制性毒性。
  • 中位随访50个月未见新的安全性信号,2级毒性在3个队列分别为13%、7%和10%(P=0.9),无3至5级毒性。
  • 局部失败率在3个治疗组分别为9%、3%和6%(P=0.5),4年局部失败总体累积风险为7%(95%CI 2-12)。
  • 中位无进展生存期为16.5个月(95%CI 9.8-21.5),4年无进展生存率为21%(95%CI 14-32)。
  • 中位总生存期在各组均未达到(95%CI 52.8-未达到),4年总生存率为68%(95%CI 59-78);23%的患者保持长期无病,37%首次复发时为寡进展性疾病,40%出现多转移复发。

局限性

  • 乳腺和前列腺癌在本研究中代表性不足,将这些结果推广至乳腺和前列腺癌以外时需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Stereotactic body radiation therapy is increasingly used for oligometastatic disease as well as palliation, but treatment protocols for nonspine bone and nodal metastases are lacking, with a wide variety of schedules applied. METHODS AND MATERIALS: A prospective dose-escalation trial was initiated, involving 90 patients, among whom 52 (58%) had primary prostate tumors, 13 had breast tumors (14%), and 25 (28%) had other primary tumor types. All visible lymph node or nonspine bone oligometastases were treated in 3 consecutive cohorts: 5 × 7.0 Gy, 3 × 10.0 Gy, or 1 × 20.0 Gy. RESULTS: Initial results revealed no dose-limiting toxicity after a median follow-up of 17.2 months. This update provides information on long-term toxicity, local failure (LF), and progression-free survival (PFS). After a median follow-up of 50 months, no new safety signals were observed. Grade 2 toxicity was 13%, 7% and 10% in the respective cohorts (P = .9), without grade 3 to 5 toxicities. LF rates were 9%, 3%, and 6% (P = .5) for the respective treatment groups, with an overall cumulative risk of LF of 7% (95% CI, 2-12) at 4 years. Median PFS was 16.5 months (95% CI, 9.8-21.5), and 4-year PFS was 21% (95% CI, 14-32). Median overall survival across groups was not reached (95% CI, 52.8 - not reached), 4-year OS was 68% (95% CI, 59-78). A subset of patients (23%) remained long-term disease-free, 37% had oligoprogressive disease at first recurrence and 40% developed polymetastatic relapse. CONCLUSIONS: The safe and effective use of dose-escalated single-fraction stereotactic body radiation therapy for bone and lymph node metastases is supported by this trial, especially considering patient-convenience and cost-effectiveness. Caution is needed when generalizing these outcomes beyond breast and prostate cancer, given their underrepresentation in our study.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Mercier C, Billiet C, Ost P, et al. Long-Term Results of a Phase 1 Dose Escalation Trial of Ablative Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2023. PMID: 38151189. doi:10.1016/j.ijrobp.2023.12.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。